rosuvastatin trial summary

Aortic stenosis

All type of patients: 1 trials - ASTRONOMER

No demonstrated result

Atrial fibrillation

Patients without history of AF (primary prevention): 1 trials - GISSI HF (subgroup and ancillary study)

No demonstrated result

Cardiovascular prevention

All chronical situations: 8 trials - METEOR - JUPITER - CORONA - ASTEROID - Krum - GISSI-HF rosuvastatine - AURORA - HOPE 3

No demonstrated result

cardiovascular events by 11% (fully demonstrated)

MACE by 32% (fully demonstrated)

new-onset diabetes by 12% (harmful effect)

suggested Venous thromboembolism by 43% (not demonstrated)

suggested stroke (fatal and non fatal) by 20% (not demonstrated)

suggested Coronary event by 15% (not demonstrated)

suggested Coronary death and non fatal MI by 35% (not demonstrated)

suggested cardiac death by 26% (not demonstrated)

suggested Non fatal MI by 32% (not demonstrated)

See more clinical conditions

Diabetic patients: 1 trials - METEOR

No demonstrated result

Elderly: 1 trials - JUPITER (elderly sub group)

No demonstrated result

suggested cardiovascular events by 39% (not demonstrated)

suggested stroke (fatal and non fatal) by 45% (not demonstrated)

suggested Revascularization by 49% (not demonstrated)

High risk patients with or without LDL cholesterol elevation: 1 trials - JUPITER

MACE by 43% (fully demonstrated)

new-onset diabetes by 26% (harmful effect)

suggested Venous thromboembolism by 43% (not demonstrated)

suggested cardiovascular events by 47% (not demonstrated)

suggested stroke (fatal and non fatal) by 48% (not demonstrated)

suggested Coronary event by 54% (not demonstrated)

suggested Non fatal MI by 65% (not demonstrated)

suggested All cause death by 20% (not demonstrated)

Patient with related disease: 1 trials - ASTRONOMER

No demonstrated result

Patients with renal insufficiency (on hemodialysis or transplant): 1 trials - AURORA

No demonstrated result

Primary prevention: 2 trials - JUPITER - HOPE 3

cardiovascular events by 32% (fully demonstrated)

MACE by 32% (fully demonstrated)

suggested Venous thromboembolism by 43% (not demonstrated)

suggested stroke (fatal and non fatal) by 37% (not demonstrated)

suggested Coronary event by 35% (not demonstrated)

suggested Coronary death and non fatal MI by 35% (not demonstrated)

suggested cardiac death by 26% (not demonstrated)

suggested Non fatal MI by 65% (not demonstrated)

suggested All cause death by 12% (not demonstrated)

Women: 1 trials - JUPITER (women subgroup)

No demonstrated result

suggested cardiovascular events by 45% (not demonstrated)

Heart failure

All type of patients: 3 trials - CORONA - Krum - GISSI-HF rosuvastatine

No demonstrated result

See more clinical conditions

Venous thrombosis

secondary prevention of VTE : 1 trials - VanGogh extension

No demonstrated result

major or clinically relevant non-major bleeding by 211% (harmful effect)

suggested VTE by 73% (not demonstrated)

suggested non-fatal pulmonary embolism by 90% (not demonstrated)

suggested Major bleeding by 25518% (not demonstrated)

See more clinical conditions

All type of patients: 1 trials - VanGogh extension

No demonstrated result

major or clinically relevant non-major bleeding by 211% (harmful effect)

suggested VTE by 73% (not demonstrated)

suggested non-fatal pulmonary embolism by 90% (not demonstrated)

suggested Major bleeding by 25518% (not demonstrated)

All types of patients: 1 trials - VanGogh extension

No demonstrated result

major or clinically relevant non-major bleeding by 211% (harmful effect)

suggested VTE by 73% (not demonstrated)

suggested non-fatal pulmonary embolism by 90% (not demonstrated)

suggested Major bleeding by 25518% (not demonstrated)

Rosuvastatin cholesterol lowering intervention

Crestor

Aortic stenosis

Atrial fibrillation

Cardiovascular prevention

Heart failure

Venous thrombosis